CooperVision Launches MyDay® MiSight® 1 Day Contact Lenses for Myopia Control
In an important initiative aimed at tackling the increasing challenge of myopia among children, CooperVision has announced the launch of its latest product, MyDay® MiSight® 1 Day contact lenses. Set to hit the market in the UK and selected European regions, these one-day soft lenses combine CooperVision's proven ActivControl® technology with advanced silicone hydrogel material found in the MyDay® lens line, offering a clinically validated solution for managing myopia.
The growing prevalence of short-sightedness, also known as myopia, is a pressing concern, particularly in younger populations. According to research, one in two children born today are projected to be myopic by the age of 20. This condition significantly impacts various aspects of a child's life, affecting school performance, sports participation, and overall quality of life. Given the rapid progression of myopia, particularly in young children, early intervention is critical.
Debbie Olive, CooperVision's Director of Business, emphasized the company’s unwavering commitment to addressing myopia both scientifically and commercially. The MyDay® MiSight® 1 Day lenses utilize modern silicone hydrogel material from CooperVision's MyDay® range while harnessing the myopia control potential that can transform young lives. Research has highlighted that ActivControl® technology can reduce the progression of myopia by approximately 50%, based on extensive clinical studies.
This long-term research has involved hundreds of thousands of children worldwide who are currently wearing lenses equipped with this technology. The innovative design of the MyDay® MiSight® lentes features distinct vision correction zones and treatment zones, providing clear sight while assisting in controlling the progression of myopia throughout the day.
Jennifer Lambert, Vice President of Myopia Management at CooperVision, noted that this innovation allows for 'constant' management of myopia, enabling children to benefit from treatment simply by wearing their contact lenses. Furthermore, the MyDay® MiSight® design facilitates a smooth transition from myopia management in children to adult lens wear, thanks to its shared material and specifications with the existing MyDay® lenses.
The MyDay® MiSight® 1 Day lenses will be available in varied spherical powers gradient ranging from -0.25 to -6.00 diopters in 0.25 steps, and from -6.50 to -10.00 diopters in 0.50 steps, making them widely adaptable to children's vision needs.
Parents and caregivers interested in this innovative myopia management solution can learn more about CooperVision's evidence-based approaches by visiting their website. CooperVision, a division of The Cooper Companies (Nasdaq COO), stands as a premier manufacturer of soft contact lenses, offering a comprehensive range of daily, bi-weekly, and monthly options. With a focus on cutting-edge materials and optics, CooperVision addresses various complex vision issues such as astigmatism, presbyopia, pediatric myopia, and irregular corneas.
Moreover, CooperVision's commitment extends to producing high-quality sclerals, torics, and multifocal lenses, addressing the spectrum of visual needs. Collaborating with eye care professionals, CooperVision is dedicated to delivering new perspectives and substantial benefits to both customers and users.
With a vision to help individuals enjoy life's beautiful moments, The Cooper Companies also oversees CooperSurgical, known for its focus on women's health and fertility care. The company operates from San Ramon, California, employing over 15,000 people and selling products across more than 130 countries, touching the lives of over 50 million individuals annually.
To stay updated on the latest developments regarding the MyDay® MiSight® lenses and their role in effective myopia management, customers are encouraged to check CooperVision’s resource hub. As myopia continues to rise, CooperVision's proactive measures represent a beacon of hope for children and parents alike seeking effective vision solutions.
The growing prevalence of short-sightedness, also known as myopia, is a pressing concern, particularly in younger populations. According to research, one in two children born today are projected to be myopic by the age of 20. This condition significantly impacts various aspects of a child's life, affecting school performance, sports participation, and overall quality of life. Given the rapid progression of myopia, particularly in young children, early intervention is critical.
Debbie Olive, CooperVision's Director of Business, emphasized the company’s unwavering commitment to addressing myopia both scientifically and commercially. The MyDay® MiSight® 1 Day lenses utilize modern silicone hydrogel material from CooperVision's MyDay® range while harnessing the myopia control potential that can transform young lives. Research has highlighted that ActivControl® technology can reduce the progression of myopia by approximately 50%, based on extensive clinical studies.
This long-term research has involved hundreds of thousands of children worldwide who are currently wearing lenses equipped with this technology. The innovative design of the MyDay® MiSight® lentes features distinct vision correction zones and treatment zones, providing clear sight while assisting in controlling the progression of myopia throughout the day.
Jennifer Lambert, Vice President of Myopia Management at CooperVision, noted that this innovation allows for 'constant' management of myopia, enabling children to benefit from treatment simply by wearing their contact lenses. Furthermore, the MyDay® MiSight® design facilitates a smooth transition from myopia management in children to adult lens wear, thanks to its shared material and specifications with the existing MyDay® lenses.
The MyDay® MiSight® 1 Day lenses will be available in varied spherical powers gradient ranging from -0.25 to -6.00 diopters in 0.25 steps, and from -6.50 to -10.00 diopters in 0.50 steps, making them widely adaptable to children's vision needs.
Parents and caregivers interested in this innovative myopia management solution can learn more about CooperVision's evidence-based approaches by visiting their website. CooperVision, a division of The Cooper Companies (Nasdaq COO), stands as a premier manufacturer of soft contact lenses, offering a comprehensive range of daily, bi-weekly, and monthly options. With a focus on cutting-edge materials and optics, CooperVision addresses various complex vision issues such as astigmatism, presbyopia, pediatric myopia, and irregular corneas.
Moreover, CooperVision's commitment extends to producing high-quality sclerals, torics, and multifocal lenses, addressing the spectrum of visual needs. Collaborating with eye care professionals, CooperVision is dedicated to delivering new perspectives and substantial benefits to both customers and users.
With a vision to help individuals enjoy life's beautiful moments, The Cooper Companies also oversees CooperSurgical, known for its focus on women's health and fertility care. The company operates from San Ramon, California, employing over 15,000 people and selling products across more than 130 countries, touching the lives of over 50 million individuals annually.
To stay updated on the latest developments regarding the MyDay® MiSight® lenses and their role in effective myopia management, customers are encouraged to check CooperVision’s resource hub. As myopia continues to rise, CooperVision's proactive measures represent a beacon of hope for children and parents alike seeking effective vision solutions.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.